Indivior Q3 2026 Earnings Report

Indivior EPS Results

• Actual EPS: N/A
• Consensus EPS: $1.06
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Indivior Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $329.35 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Indivior Announcement Details

• Quarter: Q3 2026
• Date: 10/29/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, October 29, 2026
• Conference Call Time: 8:00AM ET

Indivior (NASDAQ:INDV) (NASDAQ: INDV) is a specialty pharmaceutical company focused on developing and commercializing treatments for substance use disorders and serious mental health conditions. The company’s primary focus is opioid use disorder, with products designed to support patients through medication-assisted treatment and recovery.

Indivior’s portfolio includes Sublocade, an extended-release injectable formulation of buprenorphine; Suboxone, a buprenorphine and naloxone product available in sublingual formulations; and Perseris, an extended-release injectable formulation of risperidone for schizophrenia. The company also markets Opvee, a nalmefene nasal spray intended for the emergency treatment of opioid overdose in adults and pediatric patients.

The company was established as an independent business in 2014 following its separation from Reckitt Benckiser. Indivior is headquartered in Richmond, Virginia, and serves patients and healthcare providers primarily in the United States, as well as in selected international markets. Its products are distributed through healthcare providers, pharmacies and other treatment channels.

Indivior is led by Chief Executive Officer Mark Crossley. The company continues to focus its research, development and commercial activities on expanding access to treatments for opioid use disorder and addressing other conditions associated with addiction and mental health.